Mesothelin, a cell surface antigen is a target for tumor-directed therapy.
Thymic carcinomas frequently demonstrate strong mesothelin expression.
High mesothelin expression in thymic carcinoma is associated with longer survival.
Mesothelin-directed therapy should be evaluated in advanced thymic carcinoma.